公开(公告)号：US07001156B2

公开(公告)日：2006-02-21

申请号：US10153772

申请日：2002-05-24

Applicant: Chih-Ming Chen

Inventor： Chih-Ming Chen

IPC: F04B17/03

CPC classification number: F04B35/04 ,  F04B39/066 ,  F04B39/121 ,  F04B39/16 ,  F04B2205/04

Abstract: An improved structure of an air inflation device is disclosed. External air is drawn to the motor and cylinder to provide rapid cooling so that the efficiency of the motor is maintained. In the present invention, a plurality of air filters is used to filter air. Thereby the air inflation device is useful and practical.

公开(公告)号：US20050287185A1

公开(公告)日：2005-12-29

申请号：US10902739

申请日：2004-07-29

Applicant: David Wong ,  Xiu Cheng ,  Chih-Ming Chen ,  Steve Jan ,  Aaron Dely ,  Dacheng Tian

Inventor： David Wong ,  Xiu Cheng ,  Chih-Ming Chen ,  Steve Jan ,  Aaron Dely ,  Dacheng Tian

IPC: A61K9/00 ,  A61K9/48

CPC classification number: A61K9/0004

Abstract: A controlled release oxybutynin tablet that employs a homogeneous core with less than 50% of a water swellable polymer and a semi-permeable membrane that surrounds the homogeneous core.

Abstract translation: 一种控制释放的奥昔布宁片剂，其使用具有小于50％的可溶胀聚合物的均质核心和围绕该均质核心的半透膜。

公开(公告)号：US06869615B2

公开(公告)日：2005-03-22

申请号：US10282820

申请日：2002-10-28

Applicant: Chih-Ming Chen ,  Unchalee Kositprapa

Inventor： Chih-Ming Chen ,  Unchalee Kositprapa

IPC: A61K9/22 ,  A61K9/24 ,  A61K9/26 ,  A61K9/28 ,  A61K9/30 ,  A61K9/32 ,  A61K9/34 ,  A61K9/36 ,  A61K9/48 ,  A61K9/50 ,  A61K9/54 ,  A61K9/58 ,  A61K9/60 ,  A61K9/62 ,  A61K31/196 ,  A61K31/415 ,  A61K31/44 ,  A61K31/4439 ,  A61K45/00 ,  A61K47/10 ,  A61P15/00 ,  A61P19/02 ,  A61P29/00 ,  A61P43/00 ,  A61K9/20

CPC classification number: A61K31/415 ,  A61K9/209 ,  A61K9/2866 ,  A61K9/4808 ,  A61K9/5078 ,  A61K31/44 ,  A61K31/195 ,  A61K2300/00

Abstract: An oral solid dosage form includes a therapeutically effective amount of an NSAID and a proton pump inhibitor in an amount effective to inhibit or prevent gastrointestinal side effects normally associated with the NSAID. Also disclosed is a method of treating a human patient in need of antiinflammatory, analgesic and/or antipyretic therapy, comprising orally administering to the patient an oral pharmaceutical dosage form which includes a therapeutically effective amount of an NSAID and an amount of a proton pump inhibitor effective to substantially inhibit gastrointestinal side effects of the NSAID. The invention is further related to a method of prophylactically treating a human patient who is on a therapy known to have significant gastrointestinal side effects or is about to begin such a therapy, via concurrent administration of an NSAID and a proton pump inhibitor in a combination (single) oral dosage form.

Abstract translation: 口服固体剂型包括治疗有效量的NSAID和质子泵抑制剂，其量有效抑制或预防与NSAID通常相关的胃肠道副作用。 还公开了一种治疗需要抗炎，止痛和/或解热治疗的人类患者的方法，其包括口服给予患者口服药物剂型，其包括治疗有效量的NSAID和量的质子泵抑制剂 有效地基本上抑制NSAID的胃肠道副作用。 本发明进一步涉及一种预防性治疗已知具有显着胃肠道副作用或将要开始这种治疗的人类患者的方法，通过同时施用NSAID和质子泵抑制剂（组合） 单一）口服剂型。

公开(公告)号：US06855599B2

公开(公告)日：2005-02-15

申请号：US10707668

申请日：2003-12-31

Applicant: Chih-Wei Hung ,  Da Sung ,  Chih-Ming Chen

Inventor： Chih-Wei Hung ,  Da Sung ,  Chih-Ming Chen

IPC: H01L21/8247 ,  H01L27/115 ,  H01L21/336

CPC classification number: H01L27/11521 ,  H01L27/115

Abstract: A flash memory device includes a substrate having a trench, a deep N-type well region in the substrate, a stacked gate structure on the substrate, a first and a second spacer on a sidewall of the stacked gate, wherein the first spacer is connected with the top of the trench, a source region in the substrate under the first spacer, a drain region in the substrate under the second spacer, a P-type well region between the stacked gate and the deep N-type well region, wherein the junction between the two well regions is higher than the bottom of the trench, a doped region along the bottom and the sidewall of the trench, wherein this doped region is connected with the source region and isolates the P-type well region from the contact formed in the trench, the contact being electrically connected to the source region.

Abstract translation: 闪速存储器件包括具有沟槽的衬底，衬底中的深N型阱区，衬底上的堆叠栅极结构，层叠栅极的侧壁上的第一和第二间隔物，其中第一间隔物连接 在沟槽的顶部，在第一间隔物下面的衬底中的源极区域，在第二间隔物下方的衬底中的漏极区域，堆叠栅极和深N型阱区域之间的P型阱区域，其中 两个阱区之间的接合点高于沟槽的底部，沿着沟槽的底部和侧壁的掺杂区域，其中该掺杂区域与源极区域连接并且将P型阱区域与形成的接触部分离开 在沟槽中，触点电连接到源极区域。

公开(公告)号：US06855336B2

公开(公告)日：2005-02-15

申请号：US10712505

申请日：2003-11-13

Applicant: Chih-Ming Chen ,  Joseph Chou ,  Unchalee Kositprapa

Inventor： Chih-Ming Chen ,  Joseph Chou ,  Unchalee Kositprapa

IPC: A61K9/16 ,  A61K9/20 ,  A61K9/28 ,  A61K9/50 ,  A61K9/52 ,  A61K9/54 ,  A61K9/56 ,  A61K31/4439 ,  A61K9/14

CPC classification number: A61K9/2846 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/1652 ,  A61K9/2013 ,  A61K9/2077 ,  A61K9/2081 ,  A61K9/284 ,  A61K9/2866 ,  A61K9/2886 ,  A61K9/5078 ,  A61K31/4439

Abstract: A stable pharmaceutical composition of omeprazole for oral administration which consists essentially of: (a) a core of Omeprazole or a pharmaceutically equivalent salt, a filler and an alkaline material selected from the group consisting of lysing and arginine; and (b) a single layer of coating on said core which comprises a layer of an enteric coating agent which is applied from an organic solvent based system.

Abstract translation: 用于口服给药的奥美拉唑的稳定药物组合物，其基本上由以下组成：（a）奥美拉唑的核心或药学上相当的盐，填充剂和选自裂解和精氨酸的碱性物质; 和（b）在所述芯上的单层涂层，其包含从基于有机溶剂的体系施加的肠溶衣层。

公开(公告)号：US06706602B2

公开(公告)日：2004-03-16

申请号：US10064667

申请日：2002-08-05

Applicant: Cheng-Yuan Hsu ,  Chi-Shan Wu ,  Chih-Ming Chen

Inventor： Cheng-Yuan Hsu ,  Chi-Shan Wu ,  Chih-Ming Chen

IPC: H01L21336

CPC classification number: H01L27/11521 ,  H01L21/28273 ,  H01L27/115

Abstract: A manufacturing method of flash memory. A substrate is provided, on which a gate structure is formed. A first spacer is formed on the sidewalls of the gate structure. A source region is formed in the substrate at one side of the gate structure. A first conductive layer and a sacrificial layer are formed on the substrate. The first conductive layer and the sacrificial layer are removed until the gate structure is exposed. A thermal oxidation process is performed to form a mask layer on the first conductive layer and the gate structure. The sacrificial layer remaining on the first conductive layer is removed, and the first conductive layer is etched with a square shape. The mask layer is removed, and a second spacer is formed on the sidewalls of the second conductive layer. A drain region is formed in the substrate at one side of the conductive layer.

Abstract translation: 闪存的制造方法。 提供了形成栅极结构的衬底。 在栅极结构的侧壁上形成第一间隔物。 源极区域形成在栅极结构的一侧的衬底中。 在基板上形成第一导电层和牺牲层。 去除第一导电层和牺牲层，直到栅极结构暴露。 进行热氧化处理以在第一导电层和栅极结构上形成掩模层。 去除残留在第一导电层上的牺牲层，并以正方形蚀刻第一导电层。 去除掩模层，并且在第二导电层的侧壁上形成第二间隔物。 在导电层的一侧的基板中形成漏极区域。

公开(公告)号：US06485748B1

公开(公告)日：2002-11-26

申请号：US08990129

申请日：1997-12-12

Applicant: Chih-Ming Chen ,  Joseph C. H. Chou

Inventor： Chih-Ming Chen ,  Joseph C. H. Chou

IPC: A61K920

CPC classification number: A61K9/0004 ,  A61K9/2826 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/2886

Abstract: A controlled release tablet is disclosed which comprises: (a) a homogeneous compressed core which comprises: (i) a medicament which is very slightly soluble to practically insoluble in water at 25° C.; (ii) a water soluble osmotic compound (iii) one or more osmotic polymers; and (b) a membrane coating which completely covers said core tablet which comprises a mixture of a: (i) a water insoluble pharmaceutically acceptable polymer; and (ii) a pH dependent polymer such as an enteric coating polymer, the weight ratio of the pH dependent polymer to the water insoluble pharmaceutically acceptable polymer being 0.1:1 to 0.75:1. A controlled release tablet which comprises: (a) a medicament (a) a homogeneous compressed core which comprises: (i) a medicament; (ii) a water soluble osmotic compound (iii) one or more osmotic polymers; and (b) a membrane coating which completely covers said core tablet which comprises a mixture of: (i) a water insoluble pharmaceutically acceptable polymer; and (ii) an enteric polymer.

Abstract translation: 公开了一种控释片剂，其包括：（a）均质压缩核心，其包含：（i）在25℃下几乎不溶于几乎不溶于水的药物;（ii）水溶性渗透化合物（iii） ）一种或多种渗透聚合物; 和（b）完全覆盖所述芯片的膜包衣，其包含以下物质的混合物：（i）水不溶性药学上可接受的聚合物; 和（ii）pH依赖性聚合物如肠溶衣聚合物，pH依赖性聚合物与水不溶性药学上可接受的聚合物的重量比为0.1:1至0.75:1。1.一种控释片剂，其包含：（a） 药物（a）均质压缩核心，其包含：（i）药物;（ii）水溶性渗透化合物（iii）一种或多种渗透性聚合物; 和（b）完全覆盖所述芯片的膜包衣，其包含以下混合物：（i）水不溶性药学上可接受的聚合物; 和（ii）肠溶性聚合物。

公开(公告)号：US06210716B1

公开(公告)日：2001-04-03

申请号：US09259133

申请日：1999-02-26

Applicant: Chih-Ming Chen ,  Jianbo Xie ,  Steve Jan

Inventor： Chih-Ming Chen ,  Jianbo Xie ,  Steve Jan

IPC: A61K914

CPC classification number: A61K9/2081 ,  A61K9/5078 ,  A61K9/5084

Abstract: A controlled release dosage form of bupropion hydrochloride which comprises: (a) a first pellet having a core of bupropion hydrochloride and hydroxypropyl methylcellulose at a weight ratio of 10:1 to 30:1 and a coating of a mixture of an acrylic resin which is soluble in acidic media and ethyl cellulose; (b) a second pellet having a core of bupropion hydrochloride and hydroxypropyl methylcellulose at a ratio of 10:1 to 30:1; an inner coating of a mixture of an acrylic resin which is soluble in acidic media and a water insoluble polymer and an outer coating which comprises an enteric coating polymer.

Abstract translation: 一种盐酸安非他酮的控释剂型，其包含：（a）具有核心的盐酸安非他酮和羟丙基甲基纤维素的重量比为10:1至30:1的第一颗粒和丙烯酸树脂的混合物的涂层，所述丙烯酸树脂是 可溶于酸性介质和乙基纤维素;（b）具有10：1至30：1比例的盐酸安非他酮核心和羟丙基甲基纤维素的第二粒料; 可溶于酸性介质的丙烯酸树脂和水不溶性聚合物的混合物的内涂层和包含肠溶衣聚合物的外涂层。

公开(公告)号：US6106862A

公开(公告)日：2000-08-22

申请号：US132796

申请日：1998-08-13

Applicant: Chih-Ming Chen ,  Joseph Chou ,  David Wong

Inventor： Chih-Ming Chen ,  Joseph Chou ,  David Wong

IPC: A61K9/00 ,  A61K9/20 ,  A61K9/22 ,  A61K9/28 ,  A61K31/64 ,  A61K9/30

CPC classification number: A61K9/2886 ,  A61K31/64 ,  A61K9/0004 ,  A61K9/2054 ,  A61K9/282 ,  A61K9/2866 ,  A61K9/2013

Abstract: An analgesic controlled release dosage form containing: (a) 40-80 weight percent of an analgesic; (b) 10-30 weight percent of a pharmaceutically acceptable filler; and (c) 10-30 weight percent of a carrier base wherein the carrier base is formed from a high molecular weight hydroxypropyl methylcellulose, a water soluble binder and optionally a water insoluble binder.

Abstract translation: 镇痛控释剂型，其含有：（a）40-80重量％的止痛剂; （b）10-30重量％的药学上可接受的填料; 和（c）10-30重量％的载体碱，其中载体碱由高分子量羟丙基甲基纤维素，水溶性粘合剂和任选的水不溶性粘合剂形成。

公开(公告)号：US6103263A

公开(公告)日：2000-08-15

申请号：US341478

申请日：1994-11-17

Applicant: Der-Yang Lee ,  Chih-Ming Chen

Inventor： Der-Yang Lee ,  Chih-Ming Chen

IPC: A61K9/20 ,  A61K9/22

CPC classification number: A61K9/2054 ,  A61K9/2018

Abstract: The invention provides a delayed-pulse controlled release pharmaceutical tablet having:(a) from 20 to 60 wt. % of a low molecular weight hydroxypropyl cellulose having a number average molecular weight of 70,000 to 90,000;(b) from 4 to 10 wt. % of a high molecular weight hydroxypropyl cellulose having a number average molecular weight of 1,100,000 to 1,200,000;(c) a pharmacologically acceptable amount of a medicament; and(d) an inert solid diluent.

Abstract translation: 本发明提供了一种延迟脉冲控释药物片，其具有：（a）20至60重量％ ％数均分子量为70,000至90,000的低分子量羟丙基纤维素; （b）4-10wt。 ％数均分子量为1,100,000至1,200,000的高分子量羟丙基纤维素; （c）药理学上可接受量的药物; 和（d）惰性固体稀释剂。